Puerto Rico Medical Research Center | Hato Rey, PR

Research site

(Unclaimed)

Location

Ponce De Leon Ave #735 Torre Auxilio Suites 401/603, Hato Rey, Puerto Rico, United States of America

Site insights

Top conditions

Top treatments

Isatuximab

MK-5684

Abiraterone Acetate

Livmoniplimab

Niraparib

Prednisone

MK-2870

Prednisone Versus Abiraterone Acetate

Pembrolizumab

Tirzepatide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 8 total trials

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE)

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus predniso...

Active, not recruiting

Metastatic Castration-sensitive Prostate Cancer

Drug: Niraparib

Drug: Prednisone

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physici...

Enrolling

Breast Neoplasms

Drug: Liposomal doxorubicin

Drug: Sacituzumab tirumotecan

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2)

Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presentin...

Active, not recruiting

Hepatocellular Carcinoma

Drug: Budigalimab

Drug: Durvalumab

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer (VERITAC-2)

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Active, not recruiting

Advanced Breast Cancer

Drug: ARV-471

Drug: Fulvestrant

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relap...

Enrolling

Plasma Cell Myeloma Refractory

Drug: SAR439459

Drug: Pegenzileukin

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metas...

Enrolling

Prostate Cancer Metastatic

Drug: Dexamethasone

Drug: Hydrocortisone